10.1038/s41591-022-02141-2 - Vorasidenib and ivosidenib in IDH1-mu...

This document has been corrected

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial

10.1038/s41591-022-02141-2

Published Online: 2023-02-23

Journal: Nature Medicine•Publisher: Springer Science and Business Media LLC

Authors: Ania Tassinari•Benjamin M. Ellingson•Elizabeth A. Maher•Ingo K. Mellinghoff•Isabel Arrillaga-Romany•Islam Hassan•Jennie W. Taylor•Jennifer L. Clarke•Katherine B. Peters•Kha Le•Lori Steelman•Marc K. Rosenblum•Min Lu•Patrick Y. Wen•Saewon Chun•Shuchi S. Pandya•Steven Schoenfeld•Sung Choe•Timothy F. Cloughesy•Youssef Toubouti

This document has been corrected

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial

10.1038/s41591-022-02141-2

Published Online: 2023-02-23

Journal: Nature Medicine

NOW

2023-07-03•Correction

Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial

10.1038/s41591-023-02473-7

* information provided by CrossRef

2023-07-03•Correction

10.1038/s41591-023-02473-7

* information provided by CrossRef

2023-02-23•Published

2023-07-03•Correction

Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial

10.1038/s41591-023-02473-7

* information provided by CrossRef

This document has been corrected

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial

10.1038/s41591-022-02141-2

Published Online: 2023-02-23

Journal: Nature Medicine•Publisher: Springer Science and Business Media LLC